Baldwin Brothers LLC MA lessened its stake in shares of Balchem Co. (NASDAQ:BCPC – Free Report) by 17.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,449 shares of the basic materials company’s stock after selling 705 shares during the period. Baldwin Brothers LLC MA’s holdings in Balchem were worth $531,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in BCPC. Vanguard Group Inc. raised its position in shares of Balchem by 3.8% in the 1st quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock worth $609,873,000 after purchasing an additional 144,423 shares during the last quarter. Conestoga Capital Advisors LLC raised its holdings in Balchem by 3.9% in the first quarter. Conestoga Capital Advisors LLC now owns 1,125,384 shares of the basic materials company’s stock worth $174,378,000 after buying an additional 42,172 shares during the last quarter. Geneva Capital Management LLC lifted its stake in shares of Balchem by 0.5% in the fourth quarter. Geneva Capital Management LLC now owns 767,211 shares of the basic materials company’s stock worth $114,123,000 after buying an additional 3,885 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Balchem by 1.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 687,485 shares of the basic materials company’s stock worth $102,265,000 after buying an additional 11,629 shares in the last quarter. Finally, Clearbridge Investments LLC grew its holdings in shares of Balchem by 0.5% during the fourth quarter. Clearbridge Investments LLC now owns 521,590 shares of the basic materials company’s stock valued at $77,587,000 after buying an additional 2,801 shares during the last quarter. 87.91% of the stock is owned by institutional investors.
Insider Activity at Balchem
In other news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total value of $1,395,387.50. Following the transaction, the senior vice president now directly owns 8,540 shares in the company, valued at approximately $1,537,627. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.25% of the stock is owned by insiders.
Balchem Stock Performance
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on BCPC shares. StockNews.com cut Balchem from a “buy” rating to a “hold” rating in a research report on Monday, July 29th. HC Wainwright boosted their price target on Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st.
Read Our Latest Stock Report on BCPC
Balchem Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
See Also
- Five stocks we like better than Balchem
- How to Calculate Stock Profit
- MarketBeat Week in Review – 8/5 – 8/9
- How to Start Investing in Real Estate
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- The Risks of Owning Bonds
- The Cannabis Sector: Profitability Takes Center Stage
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Free Report).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.